三博脑科(301293) - 2023 Q4 - 年度财报

Financial Performance - The consolidated revenue for the year 2023 was CNY 1,313.35 million, reflecting a significant increase compared to the previous year[102]. - Total operating revenue for 2023 reached ¥1,313,345,263.69, an increase of approximately 22.7% compared to ¥1,070,083,206.62 in 2022[118]. - Operating profit for 2023 was ¥141,972,361.46, compared to ¥96,124,611.18 in 2022, indicating a year-over-year increase of approximately 47.7%[118]. - Total profit for 2023 amounted to ¥118,298,558.16, an increase from ¥99,289,548.80 in 2022, representing a growth of about 19.2%[118]. - The net profit for the year 2023 reached ¥84,529,357.96, compared to ¥77,371,195.93 in 2022, reflecting an increase of approximately 9%[144]. - Net profit attributable to shareholders of the parent company was ¥78,238,115.58 in 2023, compared to ¥63,447,260.16 in 2022, representing a year-over-year increase of approximately 23.3%[144]. - The net profit after deducting non-recurring gains and losses reached ¥93,596,264.99, marking a significant 79.74% increase from ¥52,073,748.01 in 2022[191]. - The company reported a diluted earnings per share of ¥0.54, a slight increase of 1.89% from ¥0.53 in 2022[191]. Assets and Liabilities - As of December 31, 2023, the company's total assets reached CNY 3,134.09 million, an increase of 61.65% compared to the beginning of the year[67]. - The equity attributable to shareholders of the listed company was CNY 2,324.69 million, reflecting an increase of 87.94% year-to-date[67]. - The asset-liability ratio improved to 19.97%, a decrease of 8.81% from the beginning of the year[67]. - Total assets as of December 31, 2023, were ¥3,134,086,644.39, compared to ¥1,938,853,809.09 in the previous year, showing a significant increase of approximately 61.7%[118]. - Total equity attributable to shareholders reached ¥2,324,694,267.96, up from ¥1,236,933,348.76 in 2022, marking an increase of about 88%[118]. Cash Flow - The company reported cash and cash equivalents of CNY 822.12 million, up from CNY 600.39 million, which is an increase of about 37%[111]. - The cash flow from operating activities improved, contributing positively to the overall financial health[120]. - The net cash flow from operating activities was CNY 245,537,597.66, up from CNY 152,912,475.69, indicating a year-over-year increase of about 60.5%[148]. - The company reported a net cash increase of CNY 221,728,623.93, compared to CNY 107,820,285.97 in the previous year, indicating a growth of about 105.5%[148]. - The company received CNY 1,456,600,000.00 from investment recoveries, which is a significant increase from CNY 871,000,000.00 in the previous year, reflecting a growth of approximately 67.1%[150]. Shareholder Information - The company reported a total of 20,617 ordinary shareholders at the end of the reporting period, down from 21,741 at the end of the previous month[52]. - The top shareholder, TBP 3Doctors (HK) Limited, holds 15.70% of the shares, amounting to 24,869,200 shares[66]. - Zhang Yang, the actual controller, holds 10.59% of the shares, equivalent to 16,781,310 shares[70]. - The company has committed to not transferring or entrusting the management of shares held by major shareholders for 36 months post-IPO[76]. Acquisitions and Investments - In September 2023, the company's wholly-owned subsidiary acquired 100% equity of Beijing Huibokang Medical Equipment Co., Ltd. for 560.30 RMB[28]. - The company completed mergers and acquisitions, including the acquisition of 洛阳伍一一三博脑科医院有限公司 and 北京惠博康医疗器械经营有限公司[188]. - The company has ongoing investments in new technologies and product development, focusing on expanding its service offerings in the healthcare sector[113]. - The company plans to enhance its market presence through strategic partnerships and potential acquisitions in the upcoming fiscal year[113]. Risk Management and Compliance - The company emphasizes the importance of risk management in its future development outlook, advising investors to be cautious[12]. - The audit opinion for the financial statements was a standard unqualified opinion, indicating compliance with accounting standards[122]. - The company has engaged Lixin Certified Public Accountants (Special General Partnership) for auditing services, with a fee of 800,000 RMB for the year[29]. - The company has maintained a continuous relationship with the auditing firm for 4 years[29]. Operational Stability - The company has not reported any changes in its registered address or significant legal issues during the reporting period[3]. - The company has no significant changes or adjustments in its business, products, or services during the reporting period[55]. - The company has no major related party transactions during the reporting period[34]. - The company has no significant litigation or arbitration matters during the reporting period[32]. - The company has no significant contracts other than those already disclosed during the reporting period[42]. - The company has no significant debt or credit transactions with related parties during the reporting period[35]. - The company has no guarantees or financial business with related parties during the reporting period[36].